AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15089791
Drug: Structured Treatment
RxNorm normalized name: Lipid,structured (From Sunflower Oil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured Treatment and Teaching Programme (STTP) combining dietary freedom with insulin adjustment
Trial: 15089791
Drug: Current standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current standard practice for treatment of Type 1 diabetes
Trial: 12547241
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose complex therapy
Trial: 12547241
Drug: Parenteral iron
RxNorm normalized name: Iron, parenteral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral iron administration
Trial: 7662901
Drug: L‐NAME (NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NAME (NO synthase inhibitor) at doses of 40 micrograms kg‐1 injected plus 50 micrograms kg‐1 infused i.v.
Trial: 7662901
Drug: Thyrotropin releasing
RxNorm normalized name: Thyrotropin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin releasing hormone (TRH) 200 micrograms i.v.
Trial: 30270800
Drug: Aminophylline 250
RxNorm normalized name: aminophylline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline 250 mg intravenously
Trial: 14509461
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac 0.5%
Trial: 16527227
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin 0.1%
Trial: 16527227
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (ketorolac, indomethacin, artificial tears)
Trial: 10371400
Drug: Ethanol 0.0
RxNorm normalized name: ethanol 0.05 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.0 g/kg (Control)
Trial: 8660070
Drug: Intensive induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive induction therapy with additional intensification treatment (two blocks of intensification)
Trial: 8660070
Drug: No intensification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intensification treatment
Trial: 8660070
Drug: Intensive induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive induction therapy
Trial: 8660070
Drug: Intensification treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification treatment
Trial: 1997060
Drug: Propofol as
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol as an anaesthetic induction agent
Trial: 30670282
Drug: Complementary medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary medicine (CAM) use
Trial: 25792086
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate 5 g b.i.d. and CoQ10 100 mg t.i.d. orally
Trial: 11464149
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of basic vaccine trial concepts
Trial: 26643109
Drug: Eviprostat (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eviprostat (two capsules, q 8 h) for 8 weeks
Trial: 26643109
Drug: Pollen extract
RxNorm normalized name: pollen extracts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pollen extract (Cernilton) (two capsules, q 8 h) for 8 weeks
Trial: 18440315
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of immunosuppressives (Dis)
Trial: 2865148
Drug: Atenolol 200
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 200 mg (single dose)
Trial: 2865148
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg (single dose)
Trial: 2865148
Drug: Propranolol 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 320 mg (single dose)
Trial: 2865148
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg (chronic administration for 7 days)
Trial: 2865148
Drug: Nadolol 80
RxNorm normalized name: nadolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol 80 mg (chronic administration for 7 days)
Trial: 2865148
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg (chronic administration for 7 days)
Trial: 31228861
Drug: Continuous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous insulin infusion system (CIIS)
Trial: 31228861
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily insulin administrations (MDI)
Trial: 29727385
Drug: L-ornithine L-aspartate
RxNorm normalized name: L-ornithine L-aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine L-aspartate (LOLA) 6g thrice daily
Trial: 26649938
Drug: High-dose prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prolonged magnesium sulfate infusion (50 mg/kg/hr for 4 hours)
Trial: 26649938
Drug: Bolus magnesium
RxNorm normalized name: magnesium oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus magnesium sulfate (50 mg/kg over 1 hour)
Trial: 26649938
Drug: High-dose prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prolonged magnesium sulfate infusion
Trial: 24506775
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate ophthalmic solution 0.2% administered three times a day for 1 day
Trial: 24506775
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate gel 0.07% applied twice daily for 29 days
Trial: 24506775
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate gel 0.18% applied once daily for 29 days
Trial: 24506775
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate gel 0.18% applied twice daily for 29 days
Trial: 24506775
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate gel 0.5% applied once daily for 29 days
Trial: 22686073
Drug: Benazepril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (10 mg/d) in the Western medicine group (WM)
Trial: 22686073
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine treatment by syndrome typing in the Chinese medicine group (CM)
Trial: 22686073
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Benazepril and Chinese herbs in the combination group
Trial: 20511580
Drug: Telephone booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone booster intervention (weekly reinforcement of clinic advice)
Trial: 17606976
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of relapse after EF-RT
Trial: 12131112
Drug: AMR 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMR 15 group (15 microg x kg(‐1) x min(‐1) amrinone with a 1.0‐mg/kg loading dose)
Trial: 12131112
Drug: ReAMR group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReAMR group (5 microg x kg(‐1) x min(‐1) amrinone with 1.0‐mg/kg loading and reloading doses)
Trial: 10343521
Drug: Sulphasalazine (SSZ)
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulphasalazine (SSZ) 2-3 g/day
Trial: 10343521
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 7.5-15 mg/week
Trial: 10343521
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Sulphasalazine and Methotrexate (COMBI) same dose range as above
Trial: 7856896
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (50-100 micrograms)
Trial: 1974395
Drug: Priming with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priming with vecuronium (0.01 mg/kg priming dose, 4‐min priming interval, 0.14‐mg/kg intubating dose along with thiopental 4‐6 mg iv)
Trial: 1974395
Drug: Timing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timing with vecuronium (0.15‐mg/kg intubating dose given before thiopental and timed to weakness of hand grip)
Trial: 31929136
Drug: Modality treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modality treatment (Control)
Trial: 25238492
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg/d
Trial: 24104790
Drug: Oral nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nifedipine (10 mg tablet orally up to five doses)
Trial: 24104790
Drug: Intravenous labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous labetalol (escalating doses of 20, 40, 80, 80, and 80 mg)
Trial: 21221853
Drug: Panitumumab-based therapy
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab-based therapy (PBT)
Trial: 18413818
Drug: Aspirin exposure
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin exposure with ODC 316AA genotype
Trial: 18413818
Drug: Aspirin exposure
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin exposure with homozygous ODC 316AA genotype
Trial: 18413818
Drug: Aspirin exposure
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin exposure with wild-type or heterozygous genotypes
Trial: 18413818
Drug: Aspirin exposure
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin exposure with both ODC 316AA genotype
Trial: 12213665
Drug: Saturated solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saturated solution of potassium iodide (SSKI) for 10-15 days
Trial: 9828818
Drug: Immunohistochemistry using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunohistochemistry using HMB‐45 antibody
Trial: 2696850
Drug: R 76713
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R 76713 (5 mg)
Trial: 2696850
Drug: R 76713
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R 76713 (10 mg)
Trial: 2696850
Drug: R 76713
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R 76713 (20 mg)
Trial: 4887385
Drug: Phenformin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenformin (up to 300 mg daily)
Trial: 4887385
Drug: Metformin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (up to 3 g daily)
Trial: 4887385
Drug: Phenformin and
RxNorm normalized name: phenformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenformin and Metformin (combined)
Trial: 26769303
Drug: MK‐8389 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK‐8389 (oral doses once daily for 14 days)
Trial: 26769303
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral doses once daily for 14 days)
Trial: 21947316
Drug: D: ‐amphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D: ‐amphetamine 10 mg
Trial: 21947316
Drug: D: ‐amphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D: ‐amphetamine 20 mg
Trial: 15222054
Drug: Glutamine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (30 g/d for 7 days)
Trial: 15222054
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 g/d for 7 days)
Trial: 1978470
Drug: Remoxipride 75-300
RxNorm normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride 75-300 mg twice daily
Trial: 1978470
Drug: Haloperidol 5-20
RxNorm normalized name: haloperidol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 5-20 mg twice daily
Trial: 27886407
Drug: PRX002 (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRX002 (0.3, 1, 3, 10, or 30 mg/kg)
Trial: 23325325
Drug: Davunetide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Davunetide (5 and 30 mg/day)
Trial: 21876641
Drug: Imiquimod 3.75%
RxNorm normalized name: IMIQUIMOD 3.75% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 3.75% cream applied daily until complete clearance or a maximum of 8 weeks
Trial: 21876641
Drug: Imiquimod 2.5%
RxNorm normalized name: IMIQUIMOD 2.5% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 2.5% cream applied daily until complete clearance or a maximum of 8 weeks
Trial: 21876641
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied daily until complete clearance or a maximum of 8 weeks
Trial: 19570991
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aerobic plus resistance exercise (HAC)
Trial: 14981868
Drug: Lifestyle modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle modification including changes in diet and activity; no specific dosage or duration mentioned.
Trial: 14981868
Drug: Pharmacotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy or surgery; details not specified.
Trial: 9713266
Drug: Amenorrhoea after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amenorrhoea after adjuvant chemotherapy
Trial: 7978210
Drug: Lignocaine cardioplegia
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine cardioplegia (100 mg/l)
Trial: 2730828
Drug: Nicardipine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine infusion
Trial: 779298
Drug: Betamethasone 17-valerate
RxNorm normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone 17-valerate preparation (control)
Trial: 30454850
Drug: SMEDS formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMEDS formulation (500 mg EPA + DHA)
Trial: 30454850
Drug: Standard ω-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ω-3 acid EE formulation (840 mg EPA + DHA)
Trial: 30454850
Drug: SMEDS formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMEDS formulation
Trial: 26242295
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of vitamin D (100,000 IU on day 1, then 2 and 4 weeks after surgery) followed by maintenance dose (3420 IU/day)
Trial: 26242295
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by standard dose of vitamin D (3420 IU/day)
Trial: 23855173
Drug: No pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pretreatment (Control) + various bonding agents
Trial: 20883428
Drug: PAC (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAC (pantoprazole 40 mg b.i.d., amoxicillin 1.0 g b.i.d., clarithromycin 500 mg b.i.d. for 7 days)
Trial: 20883428
Drug: PBMT (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMT (pantoprazole 40 mg b.i.d., colloidal bismuth subcitrate 220 mg b.i.d, metronidazole 400 mg t.i.d., tetracycline 750 mg b.i.d. for 10 days)
Trial: 12969999
Drug: Inhaled flunisolide
RxNorm normalized name: flunisolide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled flunisolide (ICS), 1 mg, four inhalations bid for 7 days
Trial: 12969999
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (OCS), 2 mg/kg (max 60 mg/d) for 7 days
Trial: 1881720
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (Ig) therapy
Trial: 7055176
Drug: Tetracycline, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline, 500 mg, four times daily for 7 days
Trial: 7055176
Drug: Erythromycin, 500
RxNorm normalized name: Erythromycin, 500 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin, 500 mg, four times daily for 7 days
Trial: 7055176
Drug: Erythromycin, 250
RxNorm normalized name: Erythromycin, 250 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin, 250 mg, four times daily for 7 days
Trial: 7055176
Drug: Tetracycline, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline, 500 mg, four times daily for 10 days
Trial: 7055176
Drug: Sulfisoxazole, 500
RxNorm normalized name: SulfiSOXAZOLE, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfisoxazole, 500 mg, four times daily for 10 days
Trial: 7055176
Drug: Ampicillin, loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin, loading dose plus additional ampicillin for 3 to 21 days
Trial: 23689765
Drug: Oxandrolone, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone, 20 mg/d (n = 108)
Trial: 19880676
Drug: CP-690,550 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 5 mg bid
Trial: 19880676
Drug: CP-690,550 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 15 mg bid
Trial: 19880676
Drug: CP-690,550 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 30 mg bid
Trial: 18591750
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake (specific dosage and duration not mentioned)
Trial: 16616745
Drug: Serum anti-müllerian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum anti-müllerian hormone (AMH) levels in patients with premature ovarian failure (POF)
Trial: 16616745
Drug: Serum anti-müllerian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum anti-müllerian hormone (AMH) levels in patients with polycystic ovary syndrome (PCOS)
Trial: 8858270
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg (evening dose)
Trial: 8858270
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg (morning dose)
Trial: 1532974
Drug: Single drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drug therapy for induction of remission
Trial: 8099363
Drug: Single drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drug therapy for maintenance of remission at 6 months
Trial: 8099363
Drug: Single drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drug therapy for maintenance of remission at 12 months
Trial: 3548009
Drug: Meperidine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 80 mg
Trial: 3548009
Drug: Butorphanol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (4 mg) vs Meperidine (80 mg)
Trial: 24011464
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy on one side of the jaw
Trial: 19956085
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg DMXB-A
Trial: 19956085
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg DMXB-A
Trial: 15895328
Drug: Function-centered treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Function-centered treatment (FCT) (4h/d, 6d/wk, for 3 wk)
Trial: 15895328
Drug: Pain-centered treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain-centered treatment (PCT) (2.5h/d, 6d/wk, for 3 wk)
Trial: 6391504
Drug: Praziquantel (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (25 mg per kg of body weight, 3 times daily for one or two days)
Trial: 6391504
Drug: Praziquantel (two-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (two-day dosage schedule)
Trial: 6391504
Drug: Praziquantel (one-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (one-day dosage schedule)